Severity
Moderate
FDA Drug recall · Reported January 17, 2024
Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.
Dr. Reddy's Laboratories, Inc. recalled Tizanidine Tablets, USP 4mg, 150-count bottle, Rx only, Mfd. By: Dr. Reddy's Laboratories… - a moderate-severity action.
Tizanidine Tablets, USP 4mg, 150-count bottle, Rx only, Mfd. By: Dr. Reddy's Laboratories… was recalled by Dr. Reddy's Laboratories, Inc. in January 17, 2024. Reason: Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.. Check the official notice for the remedy. Verify recall #D-0223-2024 with the FDA Drug before acting.
The recall
Dr. Reddy's Laboratories, Inc. issued this moderate-severity FDA Drug recall-Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets..
Sourced from official FDA Drug enforcement records. Verify recall #D-0223-2024 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0223-2024) was formally reported on January 17, 2024, with the manufacturer initiating the action on January 2, 2024. It is classified under Moderate severity (Class II), with a current status of Completed. Dr. Reddy's Laboratories, Inc. is listed as the recalling firm, operating out of Princeton, NJ. Federal records list the affected scope as 38,952 bottles.
The documented reason for this recall is: Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets. Distribution data in the federal record shows the product reached: USA Nationwide. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
38,952 bottles
Related Recalls
6
0 from same agency
Tizanidine Tablets, USP 4mg, 150-count bottle, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited, Srikakulam - 532 409 INDIA, NDC 55111-180-15
Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Completed |
| Recall number | D-0223-2024 |
| Date reported | January 17, 2024 |
| Date initiated | January 2, 2024 |
| Recalling firm | Dr. Reddy's Laboratories, Inc. |
| Firm location | Princeton, NJ |
| Affected scope | 38,952 bottles |
| Distribution | USA Nationwide |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 17, 2024. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.